Jetoptera Executes FETT for FTC-250 at Paris Air Show 2025
The First Engine To Test (FETT) was evaluated at the VAN DER LEE Turbo Systems facilities in Zaandam, The Netherlands. The 250 kW turbocompressor, that is the heart of the Fluidic Propulsive System™, is a two-shaft engine using a free turbine that is mechanically coupled to a two-stage axial compressor designed to produce the appropriate flow rates and pressure ratios required by the FPS™. 'The FETT demonstrated a very smooth startup and operability when operated in a turbofan mode. The engine was instrumented in this configuration, to monitor pressure and temperature as well as thrust produced. The next step includes the performance mapping of the turbocompressor, followed by the integration with the FPS™ onto the J-500 airframe,' said Dr Andrei Evulet, CEO/CTO of Jetoptera, Inc.
The J-500 prototype is developed specifically for the UAE and MENA market and will be uniquely enabled by the FPS™ to perform unmanned cargo missions with VTOL and unmatched speed, low noise, and reliability thanks to the patented propulsion system. The modularity of the FTC-250 system allows its components to operate in turbojet, turbofan and FPS™ modes.
Jetoptera and Eanan Al Samma thank Parametric Solutions, Inc. and VAN DER LEE Turbo Systems for their critical support in the design and manufacturing of the unique FTC-250 architecture in record time.
For information about this press release please contact Todd Newton [email protected]
Jetoptera, Inc. https://www.jetoptera.com
Facebook: https://www.facebook.com/Jetoptera/
LinkedIn: https://www.linkedin.com/company/jetoptera/posts/?feedView=all
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cd349ff9-08de-40f2-bf9f-00550debd034
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
BigBear.ai (BBAI) Brings AI Cargo Security to Panama, Eyes Global Expansion
Holdings, Inc. (NYSE:BBAI) ) is one of the AI Stocks On Wall Street's Radar. On August 15, the company announced the launch of a next-generation cargo security management solution in partnership with Narval Holding Corp., through Narval's subsidiary International Shipping Compliance, S.A. (ISC), in Panama. The AI-powered cargo security management solution will begin in Panama with planned expansion across the region and worldwide. en route cargo chain-of-custody application will use biometric verification to link drivers and transport vehicles to a cargo container and its corresponding security seal. This will ensure full accountability of the cargo contents from origin to destination. The solution secures the global supply chain by enabling real-time driver and tracking monitoring with a centralized management platform. Cargo flows can be supervised with better precision, ensuring better detection of anomalies, and generation of actionable insights. A cargo ship hauled with containers on its deck, heading to a port. 'Securing the global supply chain requires innovation, trust, and the ability to verify each handoff along the way. By partnering with Narval Holding Corp. in Panama – a critical gateway for global trade – we will deliver an AI-driven solution to strengthen cargo security today, while laying the foundation for broader regional adoption and collaborations with the international shipping lines.' -Kevin McAleenan, CEO of Holdings, Inc. (NYSE:BBAI) is an artificial intelligence specialist that provides decision intelligence solutions for national security, digital identity, supply chain and logistics, enterprise operations, and manned-unmanned teaming in autonomous systems. While we acknowledge the potential of BBAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar SAN FRANCISCO, CA / / August 19, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Annual Meeting of Stockholders held on August 19, 2025 (the "Annual Meeting"). Seven proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Annual Meeting and supplemental information filed with the Securities and Exchange Commission on July 21, 2025 and as amended on August 6, 2025. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at The proxy statement is also available on the Company's corporate website. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the August 2025 Emerging Growth Conference, and statements regarding Jaguar's planned regulatory pathway to complete a supplemental NDA for crofelemer for patients with metastatic breast cancer. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Mastercard in a Spree to Boost Cross-Border Payments in the UAE
Mastercard Incorporated MA and Worldpay recently teamed up to leverage Mastercard Move and enhance money movement for consumers and businesses in the UAE. As part of this partnership, Worldpay's Push-to-Card solution will facilitate swift and seamless domestic and international card-based payouts. These include diverse use cases such as gig worker payments, insurance settlements, remittances and crypto withdrawals — all underpinned by Mastercard's strong security framework and reliable infrastructure. For consumers, this means faster access to their money, while businesses gain streamlined and more efficient payout capabilities, without the need to exchange banking details. Additionally, the solution enables Worldpay's merchants to use their existing acquiring flows to fund disbursements, simplifying processes and minimizing dependence on multiple service providers. A few days before the latest initiative, Mastercard and an UAE-based fintech Zand entered into a strategic partnership. Through the utilization of Mastercard Move's money movement solutions, the collaboration will allow Zand to deliver secure, seamless and efficient international money transfer services to its customers. Such initiatives reflect Mastercard's sincere efforts to enhance cross-border payment capabilities across the UAE and accelerate the adoption of digital transactions nationwide. Mastercard Move empowers banks, non-bank financial institutions and their customers—including direct disbursers—with secure, near-instant money transfer solutions, both within countries and across borders. The suite of solutions covers more than 200 countries, supports 150+ currencies, and reaches more than 95% of the world's banked population. The increased usage of Mastercard Move is expected to boost its cross-border volumes, which advanced 15% on a local currency basis in the second quarter of 2025. How are Competitors Faring? Some of Mastercard's competitors across the UAE include PayPal Holdings, Inc. PYPL and Visa Inc. V. PayPal boasts a significant presence in the UAE. This April, PYPL opened its first Middle East and Africa hub in Dubai, serving 80 countries. The site will boost cross-border commerce and empower businesses with AI-driven payments. Its cross-border total payment volume grew 10% year over year in the second quarter of 2025. Visa operates in the UAE and functions as a payment network, facilitating transactions for various financial institutions and their customers within the country. V cards are widely accepted throughout the UAE for both retail purchases and online transactions. Visa's cross-border volume improved 12% year over year in the third quarter of fiscal 2025. Mastercard's Price Performance, Valuation & Estimates Shares of Mastercard have gained 24.5% in the past year compared with the industry's 19.3% growth. Image Source: Zacks Investment Research From a valuation standpoint, MA trades at a forward price-to-earnings ratio of 32.44, above the industry average of 21.61. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Mastercard's 2025 earnings implies a 11.7% rise from the year-ago period. The consensus mark for revenues indicates 15.1% year-over-year growth. Image Source: Zacks Investment Research MA currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mastercard Incorporated (MA) : Free Stock Analysis Report Visa Inc. (V) : Free Stock Analysis Report PayPal Holdings, Inc. (PYPL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
